Skip to main content

Advertisement

SpringerLink
Log in

Thromboembolism prophylaxis with dabigatran leads to lower perioperative blood loss than with dalteparin in primary knee arthroplasty

  • Knee Arthroplasty
  • Published:
Archives of Orthopaedic and Trauma Surgery Aims and scope Submit manuscript

Abstract

Introduction

Low-molecular-weight heparins (LMWH) are commonly used in thrombosis prophylaxis after total knee arthroplasty. In contrast to LMWH, dabigatran etexilate is an oral and direct acting anticoagulant. The hypothesis of the present study was that blood loss occurring in total knee arthroplasty (TKA) is not greater after dabigatran etexilate than after dalteparin.

Method

All patients suffering from primary arthrosis of knee joint that had received a total knee arthroplasty were included in this retrospective case–control study. Two groups were formed (dalteparin versus dabigatran etexilate) and the perioperative blood loss was compared using the formula of Nadler (V = EBV × ln (Hct0/Hct1) [V = blood loss (l); EBV = blood volume (l); Hct0 = preoperative haematocrit; Hct1 = haematocrit on the first postoperative day].

Patients: A total of 155 patients, 61 men and 94 women, were included. The calculated blood loss differed significantly between the two groups. The blood loss was on average 1.5 ± 0.58 l [0.32–2.9 l] in the dalteparin group, compared with 1.3 ± 0.63 l [0.29–4.31 l] in the dabigatran etexilate group (p < 0.01). None of the patients of both observed groups showed clinical signs of thrombosis or pulmonary artery embolism.

Results

Dabigatran etexilate showed a lower perioperative blood loss than dalteparin by comparable safety of both drugs.

Conclusion

Whether the timing of administration or pharmacological factors were responsible for this cannot be explained by our study.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. White RH, Zhou H, Romano PS (2003) Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost 90(3):446–455

    PubMed  CAS  Google Scholar 

  2. White RH, Romano PS, Zhou H, Rodrigo J, Bargar W (1998) Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med 158(14):1525–1531

    Article  PubMed  CAS  Google Scholar 

  3. Encke A, Haas S, Sauerland S (2009) S3 - Leitlinie - Prophylaxe der venösen Thrombembolie (VTE). VASA 38(Suppl.):1–132

    Article  Google Scholar 

  4. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E (2004) The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126(3 Suppl):204S–233S

    Article  PubMed  CAS  Google Scholar 

  5. Hirsh J, O’Donnell M, Eikelboom JW (2007) Beyond unfractionated heparin and warfarin: current and future advances. Circulation 116(5):552–560

    Article  PubMed  CAS  Google Scholar 

  6. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW et al (2004) Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126(3 Suppl):338S–400S

    Article  PubMed  CAS  Google Scholar 

  7. Stern SH, Wixson RL, O’Connor D (2000) Evaluation of the safety and efficacy of enoxaparin and warfarin for prevention of deep vein thrombosis after total knee arthroplasty. J Arthroplasty 15(2):153–158

    Article  PubMed  CAS  Google Scholar 

  8. Novotny J, Konvickova L (1998) Heparin-induced thrombocytopenia. Vnitr Lek 44(5):282–287

    PubMed  CAS  Google Scholar 

  9. Mendez J, Sanchis ME, de la FR, Stolle R, Vega JM, Martinez C et al (1998) Delayed-type hypersensitivity to subcutaneous enoxaparin. Allergy 53(10):999–1003

    Google Scholar 

  10. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP et al (2007) Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 5(11):2178–2185

    Article  PubMed  CAS  Google Scholar 

  11. Wolowacz SE, Roskell NS, Plumb JM, Caprini JA, Eriksson BI (2009) Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost 101(1):77–85

    PubMed  CAS  Google Scholar 

  12. Baetz BE, Spinler SA (2008) Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases. Pharmacotherapy 28(11):1354–1373

    Article  PubMed  CAS  Google Scholar 

  13. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP et al (2007) Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 370(9591):949–956

    Article  PubMed  CAS  Google Scholar 

  14. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP et al (2007) Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 5(11):2178–2185

    Article  PubMed  CAS  Google Scholar 

  15. Eriksson BI, Friedman R (2009) Dabigatran etexilate: pivotal trials for venous thromboembolism prophylaxis after hip or knee arthroplasty. Clin Appl Thromb Hemost

  16. Wolowacz SE, Roskell NS, Plumb JM, Caprini JA, Eriksson BI (2009) Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost 101(1):77–85

    PubMed  CAS  Google Scholar 

  17. Stangier J, Rathgen K, Stähle H, Gansser D, Roth W (2007) The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Pharmacol 64:292–303

    Article  CAS  Google Scholar 

  18. Stangier J (2008) Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 47:285–295

    Article  PubMed  CAS  Google Scholar 

  19. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W (2008) The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 36:386–399

    Article  PubMed  CAS  Google Scholar 

  20. Stangier J, Rathgen K, Stähle H, Reseski K, Körnicke T, Roth W (2009) Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics. Am J Cardiovasc Drugs 9:59–68

    PubMed  CAS  Google Scholar 

  21. (2000) Committee for Proprietary Medicinal Products. Points to consider on clinical investigation of medical products for prophylaxis of intra- and postoperative venous thromboembolic risk. London: The European Agency for the Evaluation of Medicinal Products

  22. Bergqvist D (2004) Bleeding profiles of anticoagulants, including the novel oral direct thrombin inhibitor ximelagatran: definitions, incidence and management. Eur J Haematol 73(4):227–242

    Article  PubMed  CAS  Google Scholar 

  23. Stern SH, Wixson RL, O’Connor D (2000) Evaluation of the safety and efficacy of enoxaparin and warfarin for prevention of deep vein thrombosis after total knee arthroplasty. J Arthroplasty 15(2):153–158

    Article  PubMed  CAS  Google Scholar 

  24. Ginsberg JS, Davidson BL, Comp PC, Francis CW, Friedman RJ, Huo MH et al (2009) Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 24(1):1–9

    Article  PubMed  Google Scholar 

  25. Nadler SB, Hidalgo JU, Bloch T (1962) Prediction of blood volume in normal human adults. Surgery 51:224–232

    PubMed  Google Scholar 

  26. Baetz BE, Spinler SA (2008) Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases. Pharmacotherapy 28(11):1354–1373

    Article  PubMed  CAS  Google Scholar 

  27. (2000) Committee for Proprietary Medicinal Products. Points to consider on clinical investigation of medical products for prophylaxis of intra- and postoperative venous thromboembolic risk. London: The European Agency for the Evaluation of Medicinal Products

  28. Sehat KR, Evans R, Newman JH (2000) How much blood is really lost in total knee arthroplasty?. Correct blood loss management should take hidden loss into account. Knee 7(3):151–155

    Article  PubMed  Google Scholar 

  29. Bell TH, Berta D, Ralley F, Macdonald SJ, McCalden RW, Bourne RB et al (2009) Factors affecting perioperative blood loss and transfusion rates in primary total joint arthroplasty: a prospective analysis of 1642 patients. Can J Surg 52(4):295–301

    PubMed  Google Scholar 

  30. Baetz BE, Spinler SA (2008) Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases. Pharmacotherapy 28(11):1354–1373

    Article  PubMed  CAS  Google Scholar 

  31. Raskob GE, Hirsh J (2003) Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery. Chest 124(6 Suppl):379S–385S

    Article  PubMed  Google Scholar 

  32. Bjornara BT, Gudmundsen TE, Dahl OE (2006) Frequency and timing of clinical venous thromboembolism after major joint surgery. J Bone Joint Surg Br 88(3):386–391

    Article  PubMed  CAS  Google Scholar 

  33. Strebel N, Prins M, Agnelli G, Buller HR (2002) Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery? Arch Intern Med 162(13):1451–1456

    Article  PubMed  CAS  Google Scholar 

  34. Hull RD, Pineo GF, MacIsaac S (2001) Low-molecular-weight heparin prophylaxis: preoperative versus postoperative initiation in patients undergoing elective hip surgery. Thromb Res 101(1):V155–V162

    Article  PubMed  CAS  Google Scholar 

  35. Juelsgaard P, Larsen UT, Sorensen JV, Madsen F, Soballe K (2001) Hypotensive epidural anesthesia in total knee replacement without tourniquet: reduced blood loss and transfusion. Reg Anesth Pain Med 26(2):105–110

    PubMed  CAS  Google Scholar 

  36. Sharrock NE, Hargett MJ, Urquhart B, Peterson MG, Ranawat C, Insall J et al (1993) Factors affecting deep vein thrombosis rate following total knee arthroplasty under epidural anesthesia. J Arthroplasty 8(2):133–139

    Article  PubMed  CAS  Google Scholar 

  37. Meunier A, Lisander B, Good L (2007) Effects of celecoxib on blood loss, pain, and recovery of function after total knee replacement: a randomized placebo-controlled trial. Acta Orthop 78(5):661–667

    Article  PubMed  Google Scholar 

  38. Good L, Peterson E, Lisander B (2003) Tranexamic acid decreases external blood loss but not hidden blood loss in total knee replacement. Br J Anaesth 90(5):596–599

    Article  PubMed  CAS  Google Scholar 

  39. Sehat KR, Evans R, Newman JH (2000) How much blood is really lost in total knee arthroplasty?. Correct blood loss management should take hidden loss into account. Knee 7(3):151–155

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Orthopaedics, Center for Musculoskeletal Surgery, Charité–University Medicine, Charitéplatz 1, 10117, Berlin, Germany

    Doerte Matziolis, Georg Matziolis & Carsten Perka

Authors
  1. Doerte Matziolis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Georg Matziolis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Carsten Perka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Doerte Matziolis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Matziolis, D., Matziolis, G. & Perka, C. Thromboembolism prophylaxis with dabigatran leads to lower perioperative blood loss than with dalteparin in primary knee arthroplasty. Arch Orthop Trauma Surg 131, 1739–1743 (2011). https://doi.org/10.1007/s00402-011-1335-0

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00402-011-1335-0

Keywords

Search

Navigation